Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

NCT00601718 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Washington

Collaborators